A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction
PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline
Start Date
Not specified
Study Completion Date
February 28, 2007
Conditions
Acute Myocardial Infarction
Interventions
DRUG
Filgrastim
Trial Locations (1)
44195
Cleveland Clinic Foundation, Cleveland
All Listed Sponsors
lead
The Cleveland Clinic
OTHER
NCT00215124 - A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter